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Abstract: Recent years have seen many exciting developments in the treatment of rheumatoid arthritis. Tocilizumab (TCZ) is a 
­ monoclonal­antibody­which­inhibits­the­interleukin-6­receptor.­After­initial­studies­in­Japan,­it­has­been­extensively­studied­in­five­mul-
ticentre­clinical­trials.­This­report­summarises­the­key­efficacy­and­toxicity­findings­from­the­major­clinical­trials.­TCZ­works­quickly­
and­effectively­in­rheumatoid­arthritis­either­as­monotherapy­or­in­combination­with­other­agents­in­early­disease,­DMARD­inadequate­
responders,­seronegative­disease­and­after­anti-TNF­failure.­The­toxicity­profile­is­manageable­but­includes­infections­(most­notably 
skin and soft tissue), increases in serum cholesterol, transient decreases in neutrophil count and abnormal liver function tests (especially 
in­combination­with­methotrexate).­In­summary,­there­is­sufficient­evidence­to­make­TCZ­a­first­line­biologic­therapy­for­rheumatoid­
arthritis especially for those who are unable to take methotrexate or who fail anti-TNF therapy.
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Introduction
Rheumatoid­ arthritis­ is­ the­ most­ common­ inflam-
matory arthritis. There have been a number of non 
biologic  treatments  that  slow  down  radiographic 
  progression1 but generally, the effect of these agents 
was relatively modest and often limited by toxicity. 
Therapies have improved in recent years to the point 
where clinical remission can be achieved in up to 50% 
of patients with a combination of a biologic agent and 
methotrexate (MTX) or triple therapy. While this is 
very encouraging compared to ten years ago, it still 
means there are 50% of patients who get an incom-
plete response and 10%–20% who get a very limited 
response. Interleukin-6, a glycoprotein composed of 
212 amino acids in human, has pleiotropic effects on 
various cells such as B cells, T cells, hematopoietic 
stem cells, hepatocytes, megakaryocytes,   osteoclasts, 
synoviocytes, keratinocytes and myeloma cells; thus, 
it  has  a  wide  range  of  biological  activity,  includ-
ing  regulation  of  immune  responses,  support  of 
hematopoiesis,  generation  of  acute-phase  reactions 
and­ induction­ of­ inflammation­ and­ oncogenesis.2 
Therapies involving blockade of interleukin-6 func-
tions have constituted a new therapeutic strategy for 
some­inflammatory­and­autoimmune­diseases,­includ-
ing­rheumatoid­arthritis­(RA),­systemic-onset­juve-
nile idiopathic arthritis, Castleman’s disease, multiple 
myeloma and systemic lupus erythematosus (SLE).2 
This­review­will­cover­its­efficacy­and­safety­in­rheu-
matoid arthritis.
Mechanism of action, metabolism  
and pharmacokinetic profile
Initial attempts at IL-6 blockade used a monoclonal 
antibody (mAb) to human IL-6. However, adminis-
tration­of­an­early­specific­mAb­against­IL-6­resulted­
in the formation of immune complexes that prolonged 
the half-life of IL-6. This was, therefore, unsuccessful 
in blocking IL-6 activity but others have been more 
successful at developing these antibodies.3 The current 
approach  utilises  a  humanized  anti-IL-6  receptor 
  antibody, Tocilizumab (TCZ) (also known as MRA 
or Actemra). TCZ can bind to both soluble IL-6R and 
transmembrane IL-6R and inhibit IL-6 binding to its 
receptors, leading to the blockade of IL-6 signaling 
through both receptors, while not blocking the signal-
ing of other IL-6 family cytokines.4 It may also have 
an effect on autoimmunity given the the effect of IL6 
blockade on TH17 function.5 It blocks the action of 
IL-6 without increasing the IL-6 half-life.6 Single-
dose pharmacokinetic studies in both rats and mon-
keys showed that clearance of TCZ (5 and 50 mg/
kg) was slow, with a half-life (t1/2) of between 6 and 
9 days.2 TCZ has a long t1/2 in human serum (∼240 h) 
after the third dose of 8 mg/kg,7 so it can be adminis-
tered biweekly but is usually given monthly.
Efficacy
The ACR20 is a clinical response parameter estab-
lished  by  the American  College  of  Rheumatology 
(ACR) indicating a $20% decrease in the count of ten-
der­joints­and­swollen­joints­and­a­20%­improvement­
in­at­least­five­of­the­following­measures:­patient’s­
global assessment of disease, patient’s global assess-
ment of physical function, physician’s global assess-
ment of disease and CRP or ESR. ACR50 and ACR70 
responses  indicate  50%  and  70%    improvements, 
respectively.
An  early  open  clinical  study  suggested  that 
TCZ­ was­ quite­ effective­ in­ the­ treatment­ of­ RA­
with .80% of patients achieving ACR20 responses 
and .30% achieving ACR50 responses.7­The­major­
clinical trials are outlined in Tables 1 and 2.8–16 It 
can­be­seen­that­most­subjects­were­highly­active­in­
terms of their DAS28 scores at study entry. There 
was marked variation in prior therapy and disease 
duration­ between­ the­ trials­ reflecting­ differing­
entry criteria. However, it is clear that the patients 
Table 1. earlier tocilizumab monotherapy studies.
study patient population patients, n comparator arm(s)  Duration
SATORI8 MTX-IR 125 MTX alone 24 wks
SAMURAI9 DMARD-IR 306 DMARDs 52 wks
CHARISMA10 MTX-IR 359 Tocilizumab + MTX; 
MTX alone
16 wks
STReAM11 DMARD-IR 143 N/A 5 yrsTocilizumab in rheumatoid arthritis
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included­reflect­the­more­severe­end­of­the­spectrum­
of patients seen in everyday rheumatology practice.
Monotherapy
In a randomized, double-blind, controlled Phase II   
trial  (the  Chugai  Humanized Anti-Human  Recom-
binant Interleukin-6 Monoclonal Antibody or CHA-
RISMA  study),10  patients  with  active  RA  and  an 
inadequate­ response­ to­ methotrexate­ (MTX)­ were­
entered­ into­ four­ treatment­ arms:­ TCZ­ 2,­ 4­ and­
8 mg/kg (n = 53, 54 and 52, respectively; four infu-
sions every 4 weeks plus MTX placebo once weekly 
at week 12) or MTX 10–25 mg/week plus placebo 
infusions (n = 49). A dose response was observed and 
tocilizumab at dose of 8 mg/kg was most effective. 
TCZ­8­mg/kg­monotherapy­was­significantly­supe-
rior to MTX alone for reducing the Disease Activity 
Score­using­a­28-joint­count­(DAS28)­as­well­as­for­
normalizing CRP and ESR. The ACR20 response in 
the MTX group was lower than in the TCZ mono-
therapy groups.10
In  an  international  multicenter,  randomized, 
  double-blind trial The Actemra versus Methotrexate 
double-Blind Investigative Trial In   mONotherapy, 
AMBITION  study,15  RA  patients  (n  =  572)  with 
moderate-to-severe  active  RA  and  who  had  not 
failed  previous  MTX  or  biologic  therapy  were 
randomized to receive either TCZ (8 mg/kg every 
4 weeks, n = 286) or MTX (7.5 mg/week titrated 
to  #20  mg/week  within  8  weeks,  n  =  284)  for 
24 weeks. In the intention to treat analyses, TCZ was 
superior­to­MTX,­with­a­significantly­higher­propor-
tion in tocilizumab group achieving ACR responses 
(Fig.  1).  TCZ  treatment  for  24  weeks  achieved 
DAS28 remission (.5 times odds), normalized CRP 
(high sensitivity CRP , 0.3 mg/dL; 89% with TCZ 
versus 31% with MTX) and improved   hemoglobin 
levels­(mean­change­from­baseline:­+1.2 g/dl versus 
+0.1 g/dl with MTX) and these effects were greater 
than those with MTX   treatment.13 In   addition, TCZ 
seemed­to­work­regardless­of­whether­the­subject­was­
rheumatoid factor positive or negative (Fig. 2). Prior 
disease modifying anti-rheumatic drugs (DMARDs) 
or­methotrexate­did­not­influence­efficacy,­however,­
both TCZ and methotrexate were more effective in 
those with a disease duration under 2 years.17 DAS28 
remission rates are outlined in Figure 3 for all the key 
international trials. These show consistent remission 
rates with the highest in LITHE16 where the data is 
recorded at 12 months rather than 24 weeks suggest-
ing­increasing­efficacy­over­time.
Other  clinical  trials  all  showed  that  targeting 
IL-6 by TCZ monotherapy was effective in reducing 
clinical symptoms, improving general health status 
and­normalizing­inflammatory­markers.8–11   Overall, 
there  have  been  .1,300  patients  participating  in 
TCZ monotherapy trials (including other doses) with 
ACR20 response of 63%–80% and ACR50 response 
of 40%–64% in the 8 mg/kg group, which were higher 
than with MTX therapy.
Table 2. Phase 3 international program.
OpTIOn12 TOWARD13 RADIATe14 AMBITIOn15 LITHe16
Study description Reducing signs  
and symptoms
Reducing signs  
and symptoms
Reducing signs  
and symptoms
Reducing signs  
and symptoms
Structural 
damage
Population MTX-IR DMARD-IR Anti-TNF-IR 6 mo MTX-free MTX-IR
Treatment TCZ + MTX TCZ + DMARDs TCZ + MTX TCZ vs. MTX TCZ + MTX
Duration 6 mo study 6 mo study 6 mo study 6 mo study 2 yr study
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Figure 1. Efficacy of tocilizumab compared to methotrexate in the AMBI-
TION trial. Tocilizumab was statistically superior to methotrexate for all 
endpoints in this figure. 
note: Reproduced from15 with permission. All P , 0.05.Jones and Ding
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Combination therapy
In  a  double-blind,  randomized,  placebo-controlled, 
parallel group Phase III study (tOcilizumab Pivotal 
Trial­in­methotrexate­Inadequate­resONders,­OPTION­
study),12 623 patients with moderate-to-severe active 
RA  were  randomly  allocated  to  receive TCZ  8  or 
4 mg/kg (n = 205 and 214, respectively), or placebo 
(n = 204) i.v. every 4 weeks, with MTX at stable pre-
study doses (10–25 mg/week) for 24 weeks. Over   
24 weeks, more patients in the placebo group (34%) 
than in the TCZ groups (15% and 9%) switched to 
rescue therapy. By week 24, the ACR20 response in 
the placebo group was lower than in the 4 and 8 mg/kg 
groups, respectively. The ACR50 and ACR70 (12 and 
22% in 4 and 8 mg/kg groups, respectively,   versus 
2% in placebo group, all P , 0.001) responses in 
tocilizumab groups were also greater than in the pla-
cebo group. Similar to other trials, TCZ 8 mg/kg nor-
malized CRP and ESR by week 2 of treatment and 
these remained normal until the end of the study but 
the effects of 4 mg/kg were less striking suggesting 
8 mg/kg is the ideal dose. Rheumatoid factor con-
centrations had decreased from baseline more in both 
TCZ groups than in the placebo group by week 24.
The  Tocilizumab  in  cOmbination  With  tradi-
tional disease modifying anti-rheumatic drug therapy 
(TOWARD)  study  was  a  double-blind,  placebo-
controlled,  multicenter  Phase  III  study  examining 
the­efficacy­of­TCZ­in­combination­with­a­range­of­
DMARDs  for  treatment  of  moderate-to-severe  RA 
patients­with­inadequate­response­to­these­agents.13   
A total of 1,220 patients, who had received stable 
doses of permitted DMARDs for $8 weeks before 
study­entry,­were­randomized­(2:1­ratio)­to­receive­
TCZ 8 mg/kg or placebo (control group) every 4 weeks 
for  24  weeks.  Overall,  751  patients  (93%  includ-
ing 2% receiving rescue therapy) in the tocilizumab 
group and 370 patients (89% including 11% receiv-
ing rescue therapy) in the control group completed   
24 weeks’ treatment. At week 24, the TCZ group had a 
greater ACR20 response than placebo group irrespec-
tive of the types and number of concurrent DMARDs 
used. The TCZ group also had greater ACR50 and 
ACR70 (21 versus 3%, P , 0.0001) responses than 
the placebo group.
A Phase III, randomized, double-blind, placebo-
controlled,  parallel  group  study  (The  Research  on 
Actemra Determining effIcacy after Anti-TNF fail-
ures,­ RADIATE­ study)­ examined­ the­ efficacy­ and­
safety  of  TCZ  with  MTX  in  patients  with  active 
RA who had failed at least one tumour necrosis fac-
tor (TNF) antagonist.14 A total of 499 patients who 
discontinued  one  or  more TNF  antagonists  due  to 
inadequate­response­before­the­study­were­randomly­
assigned to receive TCZ 4 or 8 mg/kg (n = 163 and 
175, respectively) or placebo (control, n = 160) i.v. 
every 4 weeks for 24 weeks. Over 24 weeks, 84% 
patients (87% in 8 mg/kg group, 85% in 4 mg/kg 
group  and  79%  in  placebo  group)  completed  the 
study, and more patients in the control (41%) received 
rescue therapy after week 16 compared with 19% of 
patients in 4 mg/kg group and 11% in the 8 mg/kg 
group. Despite this refractory patient selection, ACR 
responses were greater in the TCZ groups than in the 
control­group­with­a­significant­dose­response­between­
4­and­8­mg/kg.­The­efficacy­of­TCZ­was­similar­irre-
spective of the number of previous TNF agents.
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Figure 2. Effect of rheumatoid factor on ACR20 response in the AMBI-
TION trial. Tocilizumab was superior to methotrexate in both groups but 
the magnitude of benefit appeared greater in the seronegative arm pri-
marily due to methotrexate being much less effective.
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Figure  3.  DAS28  remission  rates  for  tocilizumab  8  mg/kg  versus 
  comparator in the international phase 3 program. Tocilizumab was statis-
tically superior to all comparators for DAS28 remission.Tocilizumab in rheumatoid arthritis
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Overall, there were .3,600 patients refractory to 
MTX or anti-TNF antagonists participating in TCZ in 
combination with either MTX or other DMARDs tri-
als with ACR20 responses of 50%–74% and ACR50 
responses of 29%–53% in the 8 mg/kg group.
structure Modifying effect
The  disease-modifying  effect  of TCZ  in  combina-
tion with methotrexate was determined in the LITHE 
and­OPTION­trials­by­examining­its­effects­on­joint­
erosion,­ joint­ space­ narrowing­ and­ Total­ Sharp­
Score­(TSS)­from­X-ray­films9,16 and on biochemical 
  markers.18 Over 1 year, TCZ treatment (4 or 8 mg/kg 
i.v.­ every­ 4­ weeks)­ significantly­ suppressed­ mean­
joint­erosion,­joint­space­narrowing­and­TSS­score,­
which was superior to that of methotrexate either in 
combination16 or as monotherapy.9 Compared to pla-
cebo plus MTX, TCZ 8 mg/kg plus MTX induced 
a­significant­decrease­of­a­bone­resorption­marker­
  (carboxy-terminal  telopeptide  of  type-I  collagen, 
ICTP)­at­week­16–24,­and­a­significant­decrease­of­
the  cartilage  turnover  markers  (type  IIA  collagen 
N-propeptide, PIIANP and type II collagen helical 
peptide, Helix-II) at week 4–24.18
safety and Tolerability
There are similarities for safety in most of the phase 3 
program. In AMBITION,15 the overall incidence of 
AEs was similar in both groups (79.9% TCZ vs. 77.5% 
methotrexate; P = 0.48), as was the incidence of seri-
ous AEs. Most AEs were mild or moderate, with fewer 
than 7% of patients experiencing severe AEs.
The  most  common  AEs  during  the  study  were   
infections  (TCZ,  34.4%  vs.  methotrexate,  37.3%). 
Infection  rates  per  patient  year  were  similar  (TCZ, 
1.06% vs. methotrexate, 1.09%). Skin and subcutane-
ous­infections­were­reported­with­a­higher­frequency­
in the TCZ (4.1%) vs. methotrexate group (0.7%). The 
incidence of herpes infection was similar in the two 
treatment groups (1.7% vs. 1.4%). No fungal infections 
were­reported­in­the­TCZ­group,­but­five­patients­(1.8%)­
in the methotrexate group experienced fungal infection. 
The second most common AEs were   gastrointestinal 
disorders,­ occurring­ with­ similar­ frequency­ in­ both­
groups with no difference in   perforations. Five (1.8%) 
patients in the methotrexate group and 1 (0.3%) patient 
in the TCZ group were withdrawn from the study due 
to gastrointestinal AEs.
Infusion  reactions  (any  AE  occurring  during, 
or  within  24  hours  following  infusion)  occurred 
in 5.6% of patients in the TCZ group and 1.8% in 
the methotrexate group (P =­0.0158).­The­majority­
occurred­during­the­first­2­infusions­(TCZ:­10/16;­
­ methotrexate:­3/6);­no­serious­infusion­reactions­or­
anaphylaxis were reported.
Four patients died during the study; 1 in the meth-
otrexate group (lung cancer), and 3 in the TCZ group 
(upper gastrointestinal hemorrhage/perforation, myo-
cardial ischemia, and cardio-respiratory arrest in a 
patient with history of asthma and arrhythmia). The 
death due to gastrointestinal hemorrhage was consid-
ered by the investigator to be remotely related to treat-
ment due to short exposure to TCZ and the patient’s 
medical history (peptic ulcer), although relationship 
to treatment could not be excluded. The other 3 deaths 
were deemed unrelated to trial treatment.
Fewer elevations in alanine aminotransferase (ALT) 
to .3 × the upper limit of normal (ULN) were observed 
with  TCZ  vs.  methotrexate.  One  percent  of  TCZ-
treated patients vs. 2.5% methotrexate-treated patients 
developed elevations between 3 × and 5 × ULN; 0.3 
vs. 0.7%, respectively, developed elevations between 
.5 × and 8 × ULN, and one patient in each group 
developed elevations to .8 × ULN. Three patients in 
the TCZ group vs. 2 in the methotrexate group discon-
tinued study therapy due to aminotransferase eleva-
tions. Total bilirubin elevations .ULN and ,3 × ULN 
were seen in 0.7 and 7.6% of patients in the TCZ and 
methotrexate groups, respectively, with no elevations 
observed concurrently with aminotransferase eleva-
tions. There were no clinical signs or symptoms of 
hepatitis or hepatic dysfunction.
Increases in total cholesterol from ,200 mg/dL 
at baseline to $240 mg/dL occurred with TCZ in 
13.2% of patients compared to 0.4% with methotrex-
ate. Increases in LDL from ,100 mg/dL at baseline 
to $160 mg/dL occurred in 3.1 and 0% of patients, 
respectively.  No  patients  in  either  treatment  group 
had  changes  in  triglycerides  from  ,150  mg/dL 
to $500 mg/dL. There were no clinical symptoms 
or cardiovascular events (apart from the death men-
tioned above) reported in these patients.
More patients had transient grade 3 neutropenia 
(,1000–.500 cells/mm
3) with TCZ, 3.1% vs. meth-
otrexate, 0.4%. One patient in the placebo/TCZ sub-
study arm discontinued due to grade 4   neutropenia Jones and Ding
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(,500  cells/mm3)  and  one  patient  due  to  grade  3 
neutropenia;­both­events­resolved­without­sequelae.­
There was no correlation between neutropenia and 
infection risk. In fact, the correlation had a negative 
trend  suggesting  infections  may  be  more  likely  in 
those who don’t drop their neutrophil counts.
The  overall  infection  rates  from  four  Phase  III   
trials (OPTION, TOWARD, LITHE and RADIATE) 
were  pooled  for  analysis.19  Patients  received  com-
bination treatment with DMARDs plus tocilizumab 
8 mg/kg i.v. (n = 1,582) every 4 weeks, or placebo 
(placebo  +  DMARD;  n  =  1,170).  Over  24  weeks, 
infections­ were­ the­ most­ frequent­ type­ of­ adverse­
events observed in all groups. Serious infection rates 
were low in all groups with slightly higher rates in the 
tocilizumab group. Tuberculosis was not observed in 
all these studies unlike anti-TNF agents. The rate of 
serious infections was 5.2%, or 3.9/100 patient-years, 
with no evidence of increased risk with continued 
tocilizumab exposure over time. This is similar to 
infection rates on those on antiTNF therapy. Diabetes, 
age $65 years, a history of infection and corticoster-
oid use were associated with an increased probability 
of developing a serious infection. No association was 
observed between low neutrophil counts and serious 
infections,20 even though neutrophil counts decreased 
in a dose-dependent fashion after TCZ treatment.
Hepatic  aminotransferases  and  bilirubin  levels 
during TCZ combined therapy of patients with RA in 
four Phase III trials (OPTION, TOWARD, RADIATE 
and LITHE) were pooled for analysis.21 The incidence 
of ALT and AST abnormalities during treatment was 
higher in the TCZ combined therapy group than in 
the DMARDs group. Most of these patients did not 
require­dose­modification­to­achieve­values­equal­to­
or less than the upper limit of normal. Hepatic ami-
notransferase  elevations  were  not  associated  with 
increases in total bilirubin. In the TCZ combination 
therapy  group,  25  patients  discontinued  treatment 
due­ to­ significant­ increases­ in­ALT­ or­AST­ levels­
(more­than­fivefold­the­upper­limit­of­normal).­After­a­
median of 1.5 years of treatment, ALT and AST were 
elevated more than threefold the upper limit of normal 
in 7.6 and 2.4% of 2,562 patients, respectively. Over 
5 years of treatment, increases in AST and ALT (more 
than threefold the upper limit of normal) occurred in 
9 (6.3%) and 14 (9.8%) of 143 patients, respectively, 
but most were transient and resolved without any par-
ticular treatment.11 Greater than 3 times elevation of 
ALT was more common with methotrexate therapy 
than with TCZ monotherapy in AMBITION15 sug-
gesting that the TCZ methotrexate combination may 
not be ideal with regard to liver toxicity.
Lipid­profiles­in­patients­receiving­TCZ­for­treat-
ment of RA in four Phase III trials were also pooled.22 
Increases  from  baseline  in  total  cholesterol  (TC), 
low density lipoprotein (LDL), High density lipopro-
tein (HDL) and triglycerides were observed within 
6 weeks of initiating treatment, and these persisted 
to  week  24  in  tocilizumab-treated  patients.  Over   
1.5 years, the levels of TC, HDL, LDL and triglycer-
ides­were­elevated­from­the­first­measurement­at­week­
6, and remained elevated but without further increases 
with continued treatment. Initiation of statin treatment 
after receiving TCZ was effective in reducing LDL 
levels to below baseline values.23 The increase in lipid 
levels­may­be­secondary­to­the­control­of­inflamma-
tion and explainable by the apparent effect of IL-6 on 
lipid metabolism.24 Triglyceride levels also increased 
but this was not associated with clinical symptoms, 
particularly pancreatitis.13 In addition, the increase in 
total­TC­was­not­associated­with­an­excess­in­major­
adverse cardiovascular events in the short term. More 
patients in the TCZ groups had a greater increase in 
atherogenic index (ratio LDL/HDL) than in the con-
trol group.15 This can be balanced against the marked 
Table 3. Baseline characteristics of the tocilizumab phase three program.
OpTIOn12 TOWARD13 RADIATe14 AMBITIOn15 LITHe16
Average age 51 53 54 51 53
Baseline HAQ 1.6 1.5 1.7 1.6 1.5
Baseline DAS 6.8 6.7 6.8 6.8 6.6
weight (kg) 69.8 73.8 74.8 73.0 72.1
Duration of RA (mean) 7.6 9.8 12.0 6.4 9.3
No. prior DMARDs 1.6 1.6 2.0 1.2 1.6Tocilizumab in rheumatoid arthritis
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decrease in CRP, which is an independent cardiovas-
cular risk factor.
The  potential  development  of  anti-tocilizumab 
human  anti-human  antibodies  (HAHAs)  and  their 
effect­on­both­efficacy­and­incidence­of­allergic-type­
adverse event was evaluated in four Phase III trials 
(OPTION, TOWARD, RADIATE and AMBITION).25 
Over 24 weeks, 24 out of a total of 1,747 TCZ-treated 
patients  developed  neutralizing  (n  =  18),  Ig  class 
(n = 9) or uncharacterized (n = 4) HAHAs, with some 
patients  appearing  in  several  categories.  The  inci-
dence of neutralizing HAHAs was highest in patients 
treated with TCZ (8 mg/kg) + DMARD (n = 16), 
compared with TCZ (4 mg/kg + DMARD, n = 1; or 
tocilizumab 8 mg/kg, n =­1).­However,­the­efficacy­
remained in patients with neutralizing HAHAs with 
no­ withdrawals­ due­ to­ lack­ of­ efficacy.­A­ total­ of­  
6 patients had 12 allergic adverse events but 4 of these 
developed HAHAs before these allergic events. Of 
these 4 patients, 3 withdrew from the treatment due 
to severe anaphylactic reaction (1 patient) or moder-
ate infusion-related reactions (2 patients). Since then 
there has been one death from anaphylaxis worldwide 
suggesting careful monitoring is necessary for this 
rare­side­effect­during­the­first­5–6­infusions.
The suggested management for TCZ side effects is 
outlined in Table 4.
place in Therapy
Currently, there are many effective treatments for RA 
so it is a good time to be either a sufferer of rheuma-
toid arthritis or a rheumatologist. There is substan-
tial experience with anti-TNF agents suggesting most 
rheumatologists­will­continue­to­use­them­first­line­
in­difficult­rheumatoid­arthritis.­However,­TCZ­now­
has­sufficient­evidence­of­efficacy­in­all­the­stages­
of­rheumatoid­arthritis­to­justify­it­being­a­first-line­
biologic  agent.  Unlike,  the  anti-TNF  agents,  this 
agent works well either as monotherapy or in com-
bination whereas the anti-TNF agents do best when 
combined with methotrexate. Thus, in the not uncom-
mon  methotrexate  intolerant  patient,  TCZ  mono-
therapy now appears the treatment of choice. There 
are no data directly comparing this agent with other 
biologic agents so the only comparisons are indirect 
and­cautiously­suggest­similar­efficacy.­The­long­term­
safety remains to be determined. Despite the increase 
in lipids, the effect on cardiovascular disease might 
actually be protective given the normalisation of C 
reactive protein. We would like to see data on factors 
predicting infection risk as the neutrophil data sug-
gest this is not mediated by lower neutrophil counts. 
At present, we would be reluctant to use TCZ in those 
on corticosteroids or with diabetes mellitus given the 
increased risk of gram positive skin infections. We 
would treat cholesterol according to local guidelines 
and similarly would monitor liver function regularly 
and suspend treatment if transaminases are greater than 
3 times ULN and reinstate if they   normalised as these 
changes are often transient. Lastly, TCZ is already 
being widely used in Australia but this will increase 
once there are simpler modes of administration.
conclusions
Tocilizumab­is­the­first­agent­(biologic­or­otherwise)­
that has been shown to be superior to MTX as mono-
therapy for the signs and symptoms of   rheumatoid 
Table  4.  Side  effects  with  Tocilizumab  and  suggested 
management.
side effects Action
Skin and soft  
tissue infections
Standard antibiotic therapy.  
Omit infusion for one month 
then restart if infection has 
cleared
Abnormal liver  
function tests
Monitor monthly for  
first 6 months Cease if .5 
times ULN 
Omit for one month  
if 3–5 times ULN 
No action if ,3 times ULN 
Consider modifying  
methotrexate dose
Hypercholesterolemia Monitor 2–3 times in  
first 6 months  
and annually thereafter 
Treat with statins if elevated  
according to local guidelines
Neutropenia Monitor monthly for  
first 6 months 
Cease if ,0.5 
Omit for one month if 0.5–1 
No action if greater than one
Anaphylaxis Monitor BP more carefully 
during first 6 infusions 
Do not rechallenge if BP 
drops substantially or patient 
can’t complete a prior 
infusionJones and Ding
88  Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 2010:3
arthritis.  It  is  also  effective  in  combination  with 
methotrexate or other DMARDs. The effect is con-
sistent across all outcome measures and is rapid in 
onset at 2–4 weeks. This is especially notable for 
hemoglobin as methotrexate did not improve this in 
this­trial.­The­side­effect­profile­is­as­expected­given­
its mode of action and is largely consistent with the 
other  trials.  There  are  some  points  of  difference. 
Liver toxicity was less common with tocilizumab 
compared to methotrexate whereas the combination 
seems to be a bit more toxic in other trials compared 
to DMARDs or methotrexate alone (2,3). In other 
trials both LDL and HDL cholesterol increased but 
that  was  not  seen  AMBITION  where  only  LDL 
increased.15 The cholesterol effect may be consistent 
with­the­marked­decrease­in­inflammation­which­has­
also been observed with anti-TNF agents.24 Reas-
suringly,  there  is  no  cardiovascular  signal  at  this 
stage either in the trials or the long term open label 
studies.
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